/ Print /

Mari Edlin
Mari Edlin is a frequent contributor to Managed Healthcare Executive. She is based in Sonoma, California.
High-cost generic programs decrease drug spend in 5 plans
AMCP 2016 conference presenters from MedImpact outline their High-Cost Generic program that moves members to less-expensive, clinically relevant drug alternatives.
Predictions for the future of high-cost specialty drugs
IMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.
Five policy options to remedy value-based pricing
Value-based pricing raises concerns when it comes to drug affordability and experts discuss a call to action saying “prices no longer reflect costs.”

Pharmacists critical to success in 5 value-based models
At AMCP 2016, presenters identified five types of alternative payment models, and shared why pharmacists play a key role.
Three drug trends impacting specialty pharmacy
AMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching
Technology and specialty pharmacy: 3 positive results
At the AMCP Annul Meeting, three panelists shared real-world examples of technology that is improving patient engagement, adherence, and outcomes

Shaping specialty pharmacy’s future: 4 perspectives
At AMCP, four stakeholders representing the specialty pharmacy perspective, manufacturer perspective, payer perspective, and PBM perspective shared their thoughts on the future of specialty pharmacy.
Top ways to manage cost of infusible specialty therapies
While the high cost of specialty pharmacy is no surprise in the healthcare industry, infusibles have additional challenges. Here are the challenges that top the list, and what to do about them.
CMS unveils enhanced MTM program
CMS unveils enhanced MTM program
Model set to improve compliance, reduce costs, but reimbursement challenges remain.
Best candidates for PCSK9 inhibitors
Best candidates for PCSK9 inhibitors
PBMs, insurers use cautious approach when managing these cholesterol-lowering drugs.